Constellation Brands Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Constellation Brands Inc. Common Stock trades at $128.58 (market cap $21.50B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Constellation Brands Inc. Common Stock is far larger — about 4.4× Travere Therapeutics Inc. Common Stock's market cap, and Constellation Brands Inc. Common Stock pays a 3.24% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| STZ | TVTX | |
|---|---|---|
Market Cap | $21.50B | $4.88B |
Volume | 2,104,680 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $166.68 | $67.52 |
52-Week Low | $112.77 | $26.79 |
Enterprise Value | $31.72B | $5.01B |
Dividend Yield | 3.24% | — |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Constellation Brands, Inc. is a US producer and marketer of beer, wine, and spirits, known for importing Mexican beer brands Corona and Modelo alongside a portfolio of wine and craft spirits labels.
Read more on STZ →Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →